Posted On: 08/26/2014 8:58:45 PM
Post# of 30067
Old White Papers on LymPro- Nothing has changed folks...It's getting close! Nobody here should waver with their enthusiasm for LymPro. Like Zoom keeps telling us. IT WILL BE GOLD STANDARD...Soon!
Alzheimer’s disease is currently a very large unmet medical need, which is projected to explode in the developed world with the demographics of the aging population. Accurate and affordable diagnostic information is critical to the management of patients and to the success of therapeutic product sponsor companies as they try to develop therapies for what some estimate to be a $20 billion market. Among technologies, blood analysis is preferred among all other options. Only non-invasive tests are potentially more attractive. The Lymphocyte Proliferation (LymPro) Test ® measures the proliferative response of white blood cells to mitogenic stimulation. Based on differences observed in the response of cells from patients with Alzheimer’s disease as compared with age matched controls and patients with other dementias, it appears that the test has strong potential as a diagnostic for Alzheimer’s. We believe that the LymPro test has the potential to address these needs and is poised for clinical and commercial development. Differential cell cycle and proliferative response of peripheral white blood cells from Alzheimer’s patients has been corroborated by several groups creating a corpus of data which shows it is real. While this is consistent with the Cell Cycle Hypothesis, how central it is to the core pathophysiology of Alzheimer’s disease is still to be determined. Regardless, the diagnostic accuracy and clinical utility of the LymPro test can only be determined after investment in well designed and carefully executed clinical studies.
Alzheimer’s disease is currently a very large unmet medical need, which is projected to explode in the developed world with the demographics of the aging population. Accurate and affordable diagnostic information is critical to the management of patients and to the success of therapeutic product sponsor companies as they try to develop therapies for what some estimate to be a $20 billion market. Among technologies, blood analysis is preferred among all other options. Only non-invasive tests are potentially more attractive. The Lymphocyte Proliferation (LymPro) Test ® measures the proliferative response of white blood cells to mitogenic stimulation. Based on differences observed in the response of cells from patients with Alzheimer’s disease as compared with age matched controls and patients with other dementias, it appears that the test has strong potential as a diagnostic for Alzheimer’s. We believe that the LymPro test has the potential to address these needs and is poised for clinical and commercial development. Differential cell cycle and proliferative response of peripheral white blood cells from Alzheimer’s patients has been corroborated by several groups creating a corpus of data which shows it is real. While this is consistent with the Cell Cycle Hypothesis, how central it is to the core pathophysiology of Alzheimer’s disease is still to be determined. Regardless, the diagnostic accuracy and clinical utility of the LymPro test can only be determined after investment in well designed and carefully executed clinical studies.
(0)
(0)
